Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Authors not listed
Sanofi · 2003
Abstract
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2003). A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type. <em>Sanofi</em>. https://clinicaltrials.gov/study/NCT00104013
Vancouver
Anonymous. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type. Sanofi. 2003.
BibTeX
@misc{anon2003ARando,
title = {A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type},
author = {Anonymous},
journal = {Sanofi},
year = {2003},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Memory Pharmaceuticals 2005
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease
Otsuka Pharmaceutical Development & Commercialization, Inc. 2000
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Memory Pharmaceuticals 2007
Open access · US-GOV
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease
Medivation, Inc. 2009
Open access · US-GOV
CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease
National Center for Research Resources (NCRR)
Open access · US-GOV
Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha
NVP Healthcare 2026
Open access · US-GOV